Skip to main content
Equibles
TLSI logo

TLSI · TriSalus Life Sciences, Inc.

Track TLSI — free

Use TLSI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TLSI

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.27 -0.36 (-6.39%) At close · Aug 14
Going-concern doubt — cleared Aug 6, 2026

The latest filing no longer states the doubt (first flagged May 12, 2026).

View the 10-Q filed Aug 6, 2026
Market Cap
$324.50M
Shares
61.57M

TriSalus Life Sciences, Inc. Earnings Call Transcripts

Every quarterly earnings call for TriSalus Life Sciences, Inc. (TLSI) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲32.4% $5.19M −$1.43M '23 Q3 23-11-14 · $5.72M −$35.64M '23 Q4 24-03-12 ▲116.4% $6.46M −$13.21M '24 Q1 24-04-01 ▲59.7% $7.36M −$4.33M '24 Q2 24-08-15 ▲41.5% $7.35M −$2.40M '24 Q3 24-11-14 ▲42% $9.17M −$10.38M '25 Q1 25-05-15 ▲52.3% $11.21M −$8.29M '25 Q2 25-08-12 ▲57.4% $11.57M −$10.81M '25 Q3 25-11-13 ▲59.8% $13.21M −$9.75M '25 Q4 26-03-05 ▼2.9% $8.90M $1.54M '26 Q1 26-05-12 LATEST ▲1.7% $11.41M −$9.19M '26 Q2 26-08-06
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
TriSalus Life Sciences Second Quarter 2026 Earnings Call
Confident tone CMS G-code expanding reimbursement into OBL setting Quarterly revenue growth and commercial momentum PEDD platform and pressure-enabled drug delivery technology
Revenue
$11.41M
▲ 1.7% YoY
Diluted EPS
$-0.16
Gross margin
86.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
TriSalus Life Sciences, Inc. Q1 FY2026 Earnings Call
Positive tone Real-world evidence study / PEDD data New applications / market expansion Commercial organization expansion
Revenue
$8.90M
▼ 2.9% YoY
Diluted EPS
$0.03
Gross margin
86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
TriSalus Life Sciences, Inc. Q4 FY2025 Earnings Call
Confident tone Commercial expansion / sales force New applications beyond liver Revenue growth and guidance
Revenue
$13.21M*
▲ 59.8% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
TriSalus Life Sciences, Inc. Q3 FY2025 Earnings Call
Confident tone TriNav platform expansion Genicular artery embolization (GAE) / knee osteoarthritis Revenue growth and guidance
Revenue
$11.57M
▲ 57.4% YoY
Diluted EPS
$-0.96
Gross margin
83.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
TriSalus Life Sciences, Inc. Q2 FY2025 Earnings Call
Confident tone TriNav revenue growth and commercial momentum Nelitolimod partnership strategy TriNav FLX and product portfolio expansion
Revenue
$11.21M
▲ 52.3% YoY
Diluted EPS
$-0.27
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
TriSalus Life Sciences, Inc. Q1 FY2025 Earnings Call
Positive tone Liver embolization / TriNav adoption Nelitolimod and partnership strategy Product portfolio expansion
Revenue
$9.17M
▲ 42% YoY
Diluted EPS
$-0.39
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-14
TriSalus Life Sciences, Inc. Q3 FY2024 Earnings Call
Confident tone PERIO-03 pancreatic trial (nelitolimod) PROTECT registry for multinodular goiter (thyroid) Product launches (TriNav Large, TriGuide, TriNav 2.0)
Revenue
$7.35M
▲ 41.5% YoY
Diluted EPS
$-0.12
Gross margin
86.3%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
TriSalus Life Sciences, Inc. Q2 FY2024 Earnings Call
Confident tone Nelitolimod pipeline (PERIO trials) PEDD / TriNav technology differentiation Thyroid / PROTECT opportunity
Revenue
$7.36M
▲ 59.7% YoY
Diluted EPS
$-0.21
Gross margin
87.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-01
TriSalus Life Sciences, Inc. Q1 FY2024 Earnings Call
Confident tone Revenue growth and TriNav performance Reimbursement and clinical data for TriNav TriNav Large product launch
Revenue
$6.46M
▲ 116.4% YoY
Diluted EPS
$-0.60
Gross margin
85.0%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
TriSalus Life Sciences, Inc. Q4 FY2023 Earnings Call
Confident tone Revenue Growth and TriNav Sales Nelitolimod and Pancreatic Program Clinical Pipeline / PERIO Trials
Revenue
$5.72M*
Gross margin
89.8%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
TriSalus Life Sciences, Inc. Q3 FY2023 Earnings Call
Revenue
$5.19M
▲ 32.4% YoY
Diluted EPS
$-0.14
Gross margin
88.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts CIK 1826667 CUSIP 89680M101 13F (30d) 78 filings 78 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)